Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic RetinopathyYou must be logged in to view this page.
The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic healthYou must be logged in to view this page.
Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transferYou must be logged in to view this page.
Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseasesYou must be logged in to view this page.